Scientists at OMRF have made new findings that could pave the way for the first drug to treat aortic stenosis.
David Key had never heard of sarcoidosis—until the rare disease stole his health.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
The project will focus on comparing certain immune cells in patients with Sjögren’s to those of healthy controls.
OMRF researchers have broken new ground in understanding how the lymphatic system works.
The grant will provide Bob Axtell with $2.8 million to study NMO and investigate its similarities to other autoimmune diseases, particularly MS.